Searchable abstracts of presentations at key conferences on calcified tissues
Bone Abstracts (2013) 2 P126 | DOI: 10.1530/boneabs.2.P126

ICCBH2013 Poster Presentations (1) (201 abstracts)

The role of severity of GH deficiency on clinical and instrumental features and response to treatment in children

Anzhalika Solntsava , Olga Zagrebaeva & Hanna Mikhno


Belarusian State Medical University, Minsk, Belarus.


Aim: To determine the response to treatment, clinical and instrumental features in children with partial GH deficiency (pGHD) and severe GHD (sGHD).

Methods: We examined retrospectively 30 children with isolated GHD (stage on Tanner 1) in the Endocrinological department of University hospital (Minsk) over 2004–2012 years. Group 1 (G1) – children with pGHD (n=5) mean±S.D., age 6.3±1.4 years; group 2 (G2) – sGHD (n=25), 4.8±0.9 years (P=0.4). Children in both groups were treated with GH more than 3 years. Stimulating GH levels, height on the moment of diagnosis (H); bone X-ray with the calculation years of delay relative to chronological age on diagnosis (D1), 1 year (D2), 2 years (D3), and 3 years (D4) of treatment; magnetic resonance imaging (MRI) were analyzed. The results were processed using SPSS 17.

Results: The maximum GH levels (IU/l) in clonidine sample G1 was 14.8±0.5, G2 6.2±0.6 (P=0.6), insulin sample 5.7±1.5 and 5.6±0.4 (P=0.8). G1 was treated with GH in the average dose 0.75±0.3 mg/day, G2 0.7±0.3 (P=0.5). H G2 3rd percentile was in 5 (100%) children; G1 <3 percentile was in 13(52%), 3rd 9(36%), and 10th 3(12%) children.

Six (24%) children in G2 had been confirmed pituitary pathology by MPI (two microadenoma and four pituitary hypoplasia), G1 microadenoma in one patient.

Maturation by X-ray was delayed in both groups, the dynamics G2: D1 3.1±1.7, D2 2.4±1.2, D3 2.1±0.4 (p(D1–D2)=0.2), (p(D2–D3)=0.3), and (p(D1–D3)=0.4); G1: D1 2±1.4, D2 1.5±0.5, D3 1±0.5 (p(D1–D2)=0.1), (p(D2–D3)=0.01), and (p(D1–D3)=0.01).

Conclusions: We didn’t notice the reliable differences of bone age retardation in children with sGHD at the age of diagnosis and all years of treatment. There were the reliable reducing of bone age retardation in group with pGHD between the beginning of the treatment, 2nd (P=0.01) and 1st years (P=0.01).

Volume 2

6th International Conference on Children's Bone Health

Rotterdam, The Netherlands
22 Jun 2013 - 25 Jun 2013

ICCBH 

Browse other volumes

Article tools

My recent searches

No recent searches.